Evofem Biosciences Financials
Based on the key indicators related to Evofem Biosciences' liquidity, profitability, solvency, and operating efficiency, Evofem Biosciences is not in a good financial situation at this time. It has a very high probability of going through financial hardship in April.
With this module, you can analyze Evofem financials for your investing period. You should be able to track the changes in Evofem Biosciences individual financial statements over time to develop the understanding of its risk, liquidity, profitability, or other critical and vital indicators.
Evofem |
Understanding current and past Evofem Biosciences Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Evofem Biosciences' financial statements are interrelated, with each one affecting the others. For example, an increase in Evofem Biosciences' assets may result in an increase in income on the income statement.
The data published in Evofem Biosciences' official financial statements typically reflect Evofem Biosciences' business processes, product offerings, services, and other fundamental events. However, there are additional fundamental indicators that are easier to understand and visualize along the underlying realities that are driving Evofem Biosciences' quantitative information. For example, before you start analyzing numbers published by Evofem accountants, it's essential to understand Evofem Biosciences' liquidity, profitability, and earnings quality within the context of the Pharmaceuticals space in which it operates.
Evofem Biosciences Stock Summary
Evofem Biosciences competes with Tonix Pharmaceuticals, Sonnet Biotherapeutics, Palisade Bio, IBio, Common, and Bright Minds. Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in womens sexual and reproductive health. Evofem Biosciences, Inc. is headquartered in San Diego, California. Evofem Biosciences operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 119 people.Specialization | Healthcare, Biotechnology |
Instrument | USA OTC Stock View All |
Exchange | OTCQB Exchange |
ISIN | US30048L2034 |
CUSIP | 30048L104 64066G101 30048L203 30048L302 |
Location | California; U.S.A |
Business Address | 12400 High Bluff |
Sector | Pharmaceuticals |
Industry | Health Care |
Benchmark | Dow Jones Industrial |
Website | www.evofem.com |
Phone | 858 550 1900 |
Currency | USD - US Dollar |
Evofem Biosciences Key Financial Ratios
There are many critical financial ratios that Evofem Biosciences' investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Evofem Biosciences reports annually and quarterly.Return On Equity | -3.87 | ||||
Return On Asset | -1.25 | ||||
Target Price | 2.9 | ||||
Number Of Employees | 119 | ||||
Beta | -1.25 |
Evofem Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Evofem Biosciences's current stock value. Our valuation model uses many indicators to compare Evofem Biosciences value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Evofem Biosciences competition to find correlations between indicators driving Evofem Biosciences's intrinsic value. More Info.Evofem Biosciences is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Evofem Biosciences' earnings, one of the primary drivers of an investment's value.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in census. Note that the Evofem Biosciences information on this page should be used as a complementary analysis to other Evofem Biosciences' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Other Consideration for investing in Evofem OTC Stock
If you are still planning to invest in Evofem Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Evofem Biosciences' history and understand the potential risks before investing.
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk |